DOLBY LABORATORIES, INC.
At today's price, DOLBY LABORATORIES, INC. (DLB) is priced for -1.2% growth. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
Dolby is a licensing business, with about 93% of revenue from royalties, so the assets that matter sit off the balance sheet as patents rather than on it as plant. That makes the asset-based models understate it and puts the weight on the durability of the royalty stream. At about $52 the price inverts to roughly 1% operating-profit growth a year, an undemanding bar for a company guiding its Atmos, Vision, and imaging patents to grow about 15% and to reach nearly half of licensing revenue. The
Is DLB overvalued? See what's priced in →
404 institutional managers reported holding DLB in 13F filings for the quarter ended 2026-03-31. Together they hold about 61% of the company; the top 10 hold 37%. 62 opened new positions that quarter. Held by Vanguard Group, BlackRock, Morgan Stanley, among others. On the short side, 5.8M shares were sold short as of the 2026-06-15 count, about 6% of shares outstanding (8 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
DLB has cut its share count 6.1% over the past five years, spending $1.20B on repurchases. It pays a dividend, and has for 12 years running, raised 8 years straight; the current rate is $1.32 a share annually. Cash returned over the past three years: $335.68M in dividends and $445.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at DLB over the trailing three years: 2024: 1 buy totaling $0k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
DLB's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -9.8% | +1.7% |
| 2023-11-18 | -8.0% | +3.4% |
| 2024-02-03 | -3.5% | +2.8% |
| 2024-05-03 | +5.8% | -2.7% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
DLB's latest 8-K filings: 2026-04-30 (items 2.02, 8.01, 9.01); 2026-02-06 (items 5.07); 2026-01-29 (items 2.02, 8.01, 9.01); 2025-11-18 (items 2.02, 8.01, 9.01); 2025-11-14 (items 5.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.